Table 3. Effect of in vitro antiviral activity of FNC in combination with approved antiretroviral drugs in C8166.
| Drugs | HIV-1TC-1/PBMC | HIV-1IIIB/C8166 | ||||
| Ritor | CI | Description | Ritor | CI | Description | |
| FNC+AZT | 1∶1000 | 0.44±0.20 | synergism | 1∶1000 | 0.60±0.17a | synergism |
| FNC+3TC | 1∶1000 | 0.73±0.13 | moderate synergism | 1∶1000 | 0.61±0.12 | synergism |
| FNC+NVP | 1∶500 | 0.84±0.01 | moderate synergism | 1∶1000 | 0.64±0.22a | synergism |
| FNC+T-20 | 1∶1000 | 0.28±0.01 | strong synergism | 1∶1000 | 0.69±0.07a | synergism |
| FNC+RAL | 1∶500 | 0.82±0.04 | moderate synergism | 1∶1000 | 0.65±0.01 | synergism |
| FNC+IDV | 1∶1000 | 0.50±0.15 | synergism | 1∶1000 | 0.52±0.13a | synergism |
a. Data represent means ± standard deviation for three separate experiments. For other data represents means ± standard deviation for two separate experiments.